Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of $8.31 million. The enterprise value is $9.71 million.

Market Cap	8.31M
Enterprise Value	9.71M

Important Dates

The next estimated earnings date is Wednesday, May 20, 2026, before market open.

Earnings Date	May 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Evogene has 9.89 million shares outstanding. The number of shares has increased by 38.21% in one year.

Current Share Class	12.10M
Shares Outstanding	9.89M
Shares Change (YoY)	+38.21%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	0.69%
Owned by Institutions (%)	1.71%
Float	12.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.16
Forward PS	5.43
PB Ratio	0.69
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.54, with a Debt / Equity ratio of 0.18.

Current Ratio	4.54
Quick Ratio	3.96
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-87.82

Financial Efficiency

Return on equity (ROE) is -100.69% and return on invested capital (ROIC) is -54.69%.

Return on Equity (ROE)	-100.69%
Return on Assets (ROA)	-28.77%
Return on Invested Capital (ROIC)	-54.69%
Return on Capital Employed (ROCE)	-83.05%
Weighted Average Cost of Capital (WACC)	8.69%
Revenue Per Employee	$74,096
Profits Per Employee	-$163,173
Employee Count	52
Asset Turnover	0.13
Inventory Turnover	4.04

Taxes

In the past 12 months, Evogene has paid $1,000 in taxes.

Income Tax	1,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.28% in the last 52 weeks. The beta is 0.95, so Evogene's price volatility has been similar to the market average.

Beta (5Y)	0.95
52-Week Price Change	-29.28%
50-Day Moving Average	0.82
200-Day Moving Average	1.09
Relative Strength Index (RSI)	44.41
Average Volume (20 Days)	50,777

Short Selling Information

The latest short interest is 169,681, so 1.41% of the outstanding shares have been sold short.

Short Interest	169,681
Short Previous Month	239,261
Short % of Shares Out	1.41%
Short % of Float	n/a
Short Ratio (days to cover)	1.42

Income Statement

In the last 12 months, Evogene had revenue of $3.85 million and -$8.49 million in losses. Loss per share was -$1.08.

Revenue	3.85M
Gross Profit	-241,000
Operating Income	-13.79M
Pretax Income	-13.50M
Net Income	-8.49M
EBITDA	-13.26M
EBIT	-13.79M
Loss Per Share	-$1.08

Full Income Statement

Balance Sheet

The company has $12.96 million in cash and $2.20 million in debt, giving a net cash position of $10.76 million or $1.09 per share.

Cash & Cash Equivalents	12.96M
Total Debt	2.20M
Net Cash	10.76M
Net Cash Per Share	$1.09
Equity (Book Value)	11.98M
Book Value Per Share	-0.01
Working Capital	12.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$13.50 million and capital expenditures -$135,000, giving a free cash flow of -$13.64 million.

Operating Cash Flow	-13.50M
Capital Expenditures	-135,000
Depreciation & Amortization	524,000
Net Borrowing	-526,000
Free Cash Flow	-13.64M
FCF Per Share	-$1.38

Full Cash Flow Statement

Margins

Gross margin is -6.25%, with operating and profit margins of -357.85% and -220.22%.

Gross Margin	-6.25%
Operating Margin	-357.85%
Pretax Margin	-350.32%
Profit Margin	-220.22%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-38.21%
Shareholder Yield	-38.21%
Earnings Yield	-102.10%
FCF Yield	-164.10%

Analyst Forecast

The average price target for Evogene is $3.50, which is 345.86% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.50
Price Target Difference	345.86%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 25, 2024. It was a reverse split with a ratio of 1:10.

Last Split Date	Jul 25, 2024
Split Type	Reverse
Split Ratio	1:10

Scores

Evogene has an Altman Z-Score of -20.34 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-20.34
Piotroski F-Score	2